Genocea Biosciences Inc · OTC:GNCAQ
Genocea Biosciences — Investor Presentation (June 2018)
24 slides from Genocea Biosciences's investor presentation, Jun 8, 2018
Slide 1: Pioneering Neoantigen Vaccines
Pioneering Neoantigen Vaccines JUNE 2018
Slide 2: Disclaimer
Disclaimer This presentation contains “forward-looking” statements that are within the meaning of federal securities laws and are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include information concerning our poss
Slide 3: As Individual as the Cancer We Target
As Individual as the Cancer We Target Clinical Stage Company Selecting the Right Targets for the Right Patient UNIQUE POWERFUL APPROACH TECHNOLOGY Know, Don’t Guess ATLAS™ Platform POTENTIAL Identify new targets, The only neoantigen BEST-IN-CLASS specific to individuals, based discovery platform to
Slide 4: Summary
Summary BROAD role of neoantigens in the IO revolution PROVEN ATLAS™ antigen identification technology differentiates Genocea IMPORTANT milestones expected over next 12 months Pioneering • First neoantigen vaccine, GEN-009, entering clinic this year Neoantigen • Pipeline expansion Cancer Vaccines •
Slide 5: The Promise and Challenge of the Immuno-oncology Revolution
The Promise and Challenge of the Immuno-oncology Revolution IMMUNE THE OUR CHECKPOINT ICI REALITY OPPORTUNITY INHIBITORS (ICIs) Primary and Combo A New Class of Acquired Drugs Neoantigen Vaccines Resistance Problematic with the Right Targets to Direct T cells to Kill Tumors 1 POTENTIAL FOR: • $25B 2
Slide 6: Neoantigen Vaccines Have Come of Age
Neoantigen Vaccines Have Come of Age Ott et al., Sahin et al., 2017 Today The time is right for Schumacher, developing Schreiber, 2015 2017 next-gen Possible to neoantigen Yadav et al., vaccinate against vaccines Gubin et al, 2014 2015 neoantigens Response to neoantigens drives 2014 checkpoint inhib
Slide 7: Vaccines Are Fundamentally Comprised of Two Elements
Vaccines Are Fundamentally Comprised of 2 Elements (Neo) Antigen (Neo) Antigen Discovery Modality and and SELECTION DELIVERY Which antigens do you want What’s the mechanism for immune system to respond to? presenting antigens to the immune system? (form, vectors, signals) Industry Weakness is Most I
Slide 8: Antigen Selection: A Tough Nut to Crack
Antigen Selection: A Tough Nut to Crack OCCASIONAL REGULAR FREQUENT MUTATIONS MUTATIONS MUTATIONS Pilocytic Astrocytoma Liver Melanoma AML Head and Neck Lung Squamous ALL Kidney Clear Cell Lung Adeno Thyroid Lymphoma B Cell Stomach Kidney Chromophobe Kidney Papillary Esophagus CLL Breast Lung Small
Slide 9: Industry Recognizes Neoantigen Selection as Currently Inadequate
Industry Recognizes Neoantigen Selection as Currently Inadequate … and yet the “Skeleton Key” Sole Focus: Tumor nEoantigen SeLection Alliance Neoantigen Selection (TESLA Consortium) BIG ACADEMIA BIOTECH PHARMA 9
Slide 10: Our Unique Approach to Antigen Selection
Our Unique Approach to Antigen Selection 0111100 01 11001011 11 0100111 0010 IN SILICO EX VIVO 11101 01110 10 01111001011 01 1100 COMMON to most peers UNIQUE to Genocea PREDICTIVE DEFINITIVE biological assays in the computer algorithm-based approaches ATLAS™ platform Guess the Antigens Know the Righ
Slide 11: Differentiated from a Crowded Field
Differentiated from a Crowded Field 0111100 01 11001011 11 0100111 0010 IN SILICO EX VIVO 11101 01110 10 01111001011 01 1100 COMMON to most peers UNIQUE to Genocea PREDICTIVE DEFINITIVE biological assays in the computer algorithm-based approaches ATLAS™ platform Guess the Antigens Know the Right Ant
Slide 12: ATLAS Identifies True Neoantigens
NeoantigensATLASTM Identifies are Powerful True Neoantigens: Because they Peptides Are “Foreign” Triggering to Effectivethe Immune T cell System Responses THE CHALLENGE Identifying True Neoantigens: Peptides Triggering Effective T cell Responses CANCER PATIENTS ATLAS™ T cell Peptides Recognized T ce
Slide 13: Identifying Clinically Relevant Antigens Based on Actual Human Response
Identifying Clinically Relevant Antigens of T cells Based on Actual Human Response INPUT: Patient’s Own Antigen E. coli Presenting Cells Every Potential cLLO Neoantigen from Patient’s Own Phagocytosis Patient Tumor T cells Recall Phagosome Neoantigens Phagolysosome (pH drop) Without Potential Predic
Slide 14: ATLAS Identifies and Characterizes All Neoantigens
ATLAS™ Identifies and Characterizes All Neoantigens to Identify True Neoantigens NSCLC PATIENT IFNγ CD8+ T cell Responses CD4+ T cell Responses ‘Ineffective’ Stimulatory (Not Antigens) Neoantigens pg /ml) pg /ml) ( ( Concentration Concentration γ γ IFN “Inhibitory” Neoantigens IFN Tumor-Specific Mut
Slide 15: ATLAS True Neoantigen Identification vs. In Silico: the Data
ATLAS™ True Neoantigen Identification vs. In Silico: the Data 0111100 01 10010110 11 0100111 010 1 ININ -SILICOSILICO EX VIVO 11101 01110 10 01111001011 NetMHCpan 011 1100 Predicted BIOLOGY TOO COMPLEX ATLAS™ FOR THESE APPROACHES Inhibitory IDENTIFIES TRUE NEOANTIGENS Antigens Stimulatory 1049 Antig
Slide 16: Difficulty Predicting the Right Antigens Limits Immune Response
Difficulty Predicting the Right Antigens Limits Immune Response ... and Biologically-Relevant Measure of Immunogenicity MATTERS 0111100 01 10010110 11 0100111 010 1 ~20% ~60% IN SILICO 11101 01110 10 01111001011 011 1100 % RESPONSE TO NEOANTIGEN: ACTUAL “ENHANCED” 0 100% Significant Room for FIH TRI
Slide 17: ATLAS May Enable Better Personalized Vaccines
ATLAS™ May Enable Better Personalized Vaccines 0111100 01 10010110 11 0100111 010 1 IN SILICO EX VIVO 11101 01110 10 01111001011 011 1100 Majority of Antigens Likely INEFFECTIVE All Antigens Likely to Be EFFECTIVE, or POTENTIALLY HARMFUL Target Both T cell Subsets Empirically confirmed + CD8+ predic
Slide 18: Exciting Potential for ATLAS for Cancer Vaccines and Cell Therapy
Exciting Potential for ATLAS™ for Cancer Vaccines and Cell Therapy ADOPTIVE Discovery stage efforts Discovery stage efforts CELL THERAPY ATLAS™ True antigens for better immunogenicity CRC, NSCLC VACCINES EBV-associated cancers GEN-009 NON-PERSONALIZED PERSONALIZED 18
Slide 19: GEN-009: ATLAS Neoantigen Selection for Personalized Cancer Vaccines
GEN-009: ATLAS™ Neoantigen Selection for Personalized Cancer Vaccines Collect tumor and ATLAS™ to identify SYNTHESIZE Ship personalized blood samples, true neoantigens of VACCINE product to sequence exome CD4+ and CD8+ (synthetic long clinical site T cell responses peptides + Poly ICLC) with ATLAS™-
Slide 20: GEN-009 Clinical Program Designed to Demonstrate Superiority of ATLAS
GEN-009 Clinical Program Designed to Demonstrate Superiority of ATLAS™ Antigen Selection in Patients PHASE 1/2A STUDY OVERVIEW PART A PART B • Patient cohort: No evidence of disease, • Multiple cohorts: ICI combo with SD, PRs high risk of relapse • Objectives: safety & immunogenicity, • Multiple tum
Slide 21: ATLAS Drives Genocea Neoantigen Cancer Vaccine Pipeline and Partnership Opportunities
ATLAS™ Drives Genocea Neoantigen Cancer Vaccine Pipeline and Partnership Opportunities DESIGN, STATUS & PRE- ANTICIPATED DISCOVERY CLINICAL PHASE 1 PHASE 2 MILESTONES GEN-009 • IND accepted May 2018 IN-HOUSE 1st Generation • Immunogenicity data in PIPELINE Neoantigen Cancer Vaccine 1H 2019 GEN-010 P
Slide 22: Deep Expertise in Vaccinology and Immuno-Oncology
Deep Expertise in Vaccinology and Immuno-Oncology MANAGEMENT TEAM SCIENTIFIC ADVISORY BOARD Chip Clark President President & CEO Elizabeth Jaffe, MD Deputy Director Chair Pamela Carroll, PhD Chuck Drake, MD, PhD SVP Immuno-oncology Director of Genitourinary Oncology Kwok Wong, MD Chief of Hematology
Slide 23: Summary
Summary BROAD role of neoantigens in the IO revolution PROVEN ATLAS™ antigen identification technology differentiates Genocea IMPORTANT milestones expected over next 12 months Pioneering • First neoantigen vaccine, GEN-009, entering clinic this year Neoantigen • Pipeline expansion Cancer Vaccines •
Slide 24: Genocea Biosciences, Inc.
Genocea Biosciences, Inc. NASDAQ: GNCA Cambridge Discovery Park 100 Acorn Park Drive, 5th floor Cambridge, MA 02140 USA Phone: +1 617.876.8191 www.genocea.com
Genocea Biosciences — Investor Presentation (June 2018) on 6ix